Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Quality metrics in the management of acute stroke in Greece during the first 5 years of Registry of Stroke Care Quality (RES-Q) implementation.
Palaiodimou L, Kargiotis O, Katsanos AH, Kiamili A, Bakola E, Komnos A, Zisimopoulou V, Natsis K, Papagiannopoulou G, Theodorou A, Zompola C, Safouris A, Psychogios K, Ntais E, Plomaritis P, Karamatzianni G, Mavriki A, Koutsokera M, Lykou C, Koutroulou I, Gourbali V, Skafida A, Roussopoulou A, Kourtesi G, Papamichalis P, Papagiannopoulos S, Gryllia M, Tavernarakis A, Kazis D, Karapanayiotides T, Magoufis G, Giannopoulos S, Tsivgoulis G. Palaiodimou L, et al. Among authors: tavernarakis a. Eur Stroke J. 2023 Jan;8(1 Suppl):5-15. doi: 10.1177/23969873221103474. Epub 2023 Feb 10. Eur Stroke J. 2023. PMID: 36793743 Free PMC article.
Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial.
Vermersch P, Brieva-Ruiz L, Fox RJ, Paul F, Ramio-Torrenta L, Schwab M, Moussy A, Mansfield C, Hermine O, Maciejowski M; AB07002 Study Group. Vermersch P, et al. Neurol Neuroimmunol Neuroinflamm. 2022 Feb 21;9(3):e1148. doi: 10.1212/NXI.0000000000001148. Print 2022 May. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 35190477 Free PMC article. Clinical Trial.
Mass Sensing for the Advanced Fabrication of Nanomechanical Resonators.
Gruber G, Urgell C, Tavernarakis A, Stavrinadis A, Tepsic S, Magén C, Sangiao S, de Teresa JM, Verlot P, Bachtold A. Gruber G, et al. Among authors: tavernarakis a. Nano Lett. 2019 Oct 9;19(10):6987-6992. doi: 10.1021/acs.nanolett.9b02351. Epub 2019 Sep 11. Nano Lett. 2019. PMID: 31478676 Free PMC article.
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source.
Diener HC, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchiyama S, Kreuzer J, Cronin L, Cotton D, Grauer C, Brueckmann M, Chernyatina M, Donnan G, Ferro JM, Grond M, Kallmünzer B, Krupinski J, Lee BC, Lemmens R, Masjuan J, Odinak M, Saver JL, Schellinger PD, Toni D, Toyoda K; RE-SPECT ESUS Steering Committee and Investigators. Diener HC, et al. N Engl J Med. 2019 May 16;380(20):1906-1917. doi: 10.1056/NEJMoa1813959. N Engl J Med. 2019. PMID: 31091372 Clinical Trial.
Seasonal adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational GEPAT-SMART study.
Deftereos SN, Koutlas E, Koutsouraki E, Kyritsis A, Papathanassopoulos P, Fakas N, Tsimourtou V, Vlaikidis N, Tavernarakis A, Voumvourakis K, Arvanitis M, Sakellariou D, DeLorenzo F. Deftereos SN, et al. Among authors: tavernarakis a. BMC Neurol. 2018 Nov 6;18(1):186. doi: 10.1186/s12883-018-1179-0. BMC Neurol. 2018. PMID: 30400884 Free PMC article.
Intravenous thrombolysis for acute ischemic stroke in Greece: the Safe Implementation of Thrombolysis in Stroke registry 15-year experience.
Tsivgoulis G, Kargiotis O, Rudolf J, Komnos A, Tavernarakis A, Karapanayiotides T, Ellul J, Katsanos AH, Giannopoulos S, Gryllia M, Safouris A, Papamichalis P, Vadikolias K, Mitsias P, Hadjigeorgiou G. Tsivgoulis G, et al. Among authors: tavernarakis a. Ther Adv Neurol Disord. 2018 Jun 28;11:1756286418783578. doi: 10.1177/1756286418783578. eCollection 2018. Ther Adv Neurol Disord. 2018. PMID: 30034535 Free PMC article.
Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
Trojano M, Butzkueven H, Kappos L, Wiendl H, Spelman T, Pellegrini F, Chen Y, Dong Q, Koendgen H, Belachew S; Tysabri® Observational Program (TOP) Investigators. Trojano M, et al. Mult Scler Relat Disord. 2018 Aug;24:11-19. doi: 10.1016/j.msard.2018.04.020. Epub 2018 May 2. Mult Scler Relat Disord. 2018. PMID: 29860197 Free article.
69 results